In summary, various neutrophil subtypes and their expressed molecules—such as CD74, defensins, PDL1, MPO, NE, and NETs—hold promise as predictive biomarkers for immunotherapy in lung cancer. This evidence concerns the gene MPO and lung carcinoma.